Joint Pain Injections Market - By Injection Type, By Joint Type, By End Use – Global Forecast, 2024 – 2032

Joint Pain Injections Market Size

The global joint pain injections market size was valued at USD 3.6 billion in 2023 and is anticipated to expand at 7.7% CAGR from 2024 to 2032. The growing elderly population, combined with a rise in orthopedic issues, is poised to significantly drive the growth of the joint pain injections market.

As reported by the World Health Organization, in 2022, around 1.71 billion people worldwide were affected by musculoskeletal disorders. With the aging population on the rise, the prevalence of musculoskeletal conditions and their related functional limitations is escalating. Furthermore, swift technological advancements, alongside surging demand, are set to fuel market growth in the coming years.
 

Joint pain injections are intra-articular treatments targeting inflammatory joint conditions, including rheumatoid arthritis, psoriatic arthritis, and osteoarthritis. These injections encompass hyaluronic acid, corticosteroids, and platelet-rich plasma.
 

Joint Pain Injections Market Trends

• The surging prevalence of orthopedic disorders, including osteoarthritis, osteoporosis, and joint fractures, is projected to fuel the growth of the market.
   
• Osteoarthritis, an increasingly common joint disorder, affects a significant proportion of the population worldwide. With an aging population and rising life expectancy, the prevalence of osteoarthritis is steadily increasing, particularly in emerging markets.
   
• According to the Global RA Network in 2021, approximately 350 million people worldwide suffer from arthritis. The CDC reports that currently, around 1 in 4 (or 54.4 million) adults in the U.S. experience some form of arthritis, with this number projected to reach 78 million by 2040.
   
• Additionally, data from the IHME Global Burden of Disease Study 2019 indicates that over 57 million people in Western Europe have osteoarthritis. In 2019, osteoarthritis affected over 11 million people in Germany, 8.6 million in Italy, 8.5 million in the UK, 8.4 million in France, 6.6 million in Spain, and 1 million in Sweden.
   
• This number is expected to surge significantly in the coming years, further driving demand for joint pain injections.
   

Joint Pain Injections Market Analysis

Based on injection type, the joint pain injections market is segmented into hyaluronic acid injections, corticosteroid injections, and platelet rich plasma injections. The hyaluronic acid injections segment held 64.8% revenue share in 2023 and is projected to notable expansion at 7.9% CAGR during the forecast period.
 

• The aging population and the development of technologically advanced products are expected to drive market growth. The growing preference for minimally invasive procedures, along with the quick clinical results, is projected to propel market expansion in the coming years.
   
• Hyaluronic acid injections are employed in treating knee osteoarthritis and help promote knee joint function. This therapeutic approach is known as viscosupplementation, with around 90% of viscosupplement prescriptions indicated for knee osteoarthritis.
   
• According to the Osteoarthritis Research Society International (OARSI), corticosteroids and hyaluronic acid injections are commonly used to manage osteoarthritis, although viscosupplementation is comparatively more effective than corticosteroids. These factors are anticipated to drive market growth.
   

Based on joint type, the joint pain injections market is classified into knee, shoulder & elbow, ankle & hip, and other joint types. The knee segment is anticipated to witness substantial growth to reach USD 2.7 billion during the analysis timeframe.
 

• This high market share is largely attributed to the significant prevalence of knee-related conditions. Osteoarthritis (OA) is a chronic, degenerative joint condition characterized by gradual damage to articular cartilage and underlying bone.
   
• OA is a common rheumatic ailment that affects the majority of older adults and is accompanied by pain and joint stiffness. Additionally, joint damage leads to progressive functional limitations. According to a 2020 Lancet study, the global prevalence of knee OA was around 16.0%, with an incidence rate of 203 per 10,000 individuals.
   
• As part of the overall treatment, physical therapy, rehabilitation, non-steroidal anti-inflammatory drugs, and viscosupplementation (VS) with hyaluronic acid are commonly used. Thus, the high prevalence of knee conditions and the use of joint pain injections to treat these conditions are projected to drive market growth.
   

Based on end user, the joint pain injections market is bifurcated into hospitals, clinics, and other end users. The hospitals segment dominated the market with 56.3% revenue share in 2023 and will foresee a similar trend during the forecast timeframe.
 

• High adoption of advanced therapeutics that provide improved outcomes will drive patient preference for hospitals. Increased admissions for various orthopedic disorders, along with the availability of trained professionals, bolster the demand for joint pain injections and hip replacement devices in these facilities.
   
• Additionally, hospitals provide continuous monitoring post-surgery, design exercise regimens to restore strength, work closely with patients, and offer physical therapies. Therefore, patient preference for well-equipped facilities will support revenue growth in this segment in the near future.
   
• The rising patient inflow has further increased the product adoption rate.
   

North America region market held the largest share of 47.4% in 2023 and is set to witness substantial growth in the coming years.
 

• This large revenue share is primarily due to the increasing prevalence of arthritis and other bone-related issues, coupled with the rapid adoption of new products.
   
• The rising prevalence of orthopedic conditions in the geriatric population, an increasing number of road accidents and sports injuries, continuous therapeutic innovations, and growing demand for joint pain products are some of the key factors driving market growth in the region.
   

The U.S. joint pain injections market is poised to grow at 7.3% of CAGR to reach USD 3.1 billion by the end of the forecast period.
 

• According to the U.S. Bone & Joint Initiative, in 2021, musculoskeletal diseases affected over 50% of individuals aged 18 and above in the U.S., including nearly three out of four people aged 65 and older.
   
• This high prevalence of musculoskeletal disorders, including joint pain, drives demand for effective treatments, such as joint pain injections. With a growing aging population, the incidence of joint-related issues is expected to increase, further fueling the need for pain management solutions.
   

China joint pain injections market anticipated to witness growth in coming years.
 

• The expanding geriatric population and the rise in chronic disease incidence in China are key drivers for market progression. Increasing healthcare expenditure in developing countries, along with surging investments in R&D to introduce advanced joint pain injections, supports business growth.
   

India is expected to experience growth at significant rate in global joint pain injections market.
 

• Increasing awareness about joint health and pain management options, including joint pain injections, is leading to higher adoption rates among patients suffering from arthritis and other musculoskeletal disorders. Government-run health programs and awareness campaigns are key in spreading information and encouraging timely treatment.
   
• Rising disposable incomes and improved healthcare infrastructure in India are enabling better access to advanced pain management solutions, including joint pain injections. This economic growth also allows healthcare providers to adopt and offer innovative therapies.
   
• The entry of new market players and expansion of local manufacturing facilities are helping to reduce the cost of joint pain injections, making them more affordable and accessible across various regions. This market accessibility is expected to support the long-term growth of the market in India.
   

Joint Pain Injections Market Share

The market is fragmented in nature, with global, regional, and local small players, and manufacturers playing a key role in the industry competition. Few of the key players operating in the market include DePuy Synthes (Johnson & Johnson), Pfizer Inc., Sanofi SA, Stryker Corporation, Zimmer Biomet, Arthrex, Ferring B.V. and OrthogenRx, among others. The global market is marked by significant competition driven by innovations in product formulations and expanding applications for joint pain relief.
 

Key players such as Pfizer, Sanofi, Anika Therapeutics, and Zimmer Biomet lead the market, leveraging their established portfolios and R&D capabilities to develop advanced corticosteroids, hyaluronic acid, and other injectables that cater to chronic pain management. Emerging players and specialized companies focus on novel drug delivery systems, expanding treatment efficacy and targeting underserved segments, especially in aging populations. Strategic partnerships, product launches, and regional expansions are common as companies aim to strengthen their global presence.
 

Joint Pain Injections Market Companies

Key players operating in the joint pain injections industry include:

• Anika Therapeutics, Inc.
• Arthrex
• Bioventus
• Emcyte Corporation
• Ferring B.V.
• Lifecore Biomedical
• OrthogenRx
• Pacira BioSciences (Flexion)
• Pfizer, Inc.
• Sanofi S.A.
• Stryker Corporation
• Zimmer Biomet Holdings, Inc.
   

Joint Pain Injections Industry News:

• In December 2023, Bioventus entered into a nationwide contract with Aetna Medicare Advantage for DUROLANE, a treatment for knee osteoarthritis. This strategic agreement enabled the company to expand its customer reach and increase revenue by gaining access to more than 3 million Aetna Medicare Advantage plan members.
   
• In November 2022, Anika Therapeutics, Inc. announced that they had achieved the primary endpoint in in a Phase III Study for Cingal. This product is intended to provide long lasting pain relief to treat the pain of knee osteoarthritis (OA). The firm is focusing to get the U.S. FDA approval for the Cingal and its launch. This successful trail helped the company to increase their R&D activities and gain a competitive edge over its peers.
   

The joint pain injections market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million and volume in units from 2018 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Injection Type

• Hyaluronic acid injections
• Corticosteroid injections
• Platelet rich plasma injections

Market, By Joint Type

• Knee
• Shoulder & elbow
• Ankle & hip
• Other joint types

Market, By End Use

• Hospitals
• Clinics
• Other End Use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE